Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Data support potential for SAT-3247 in multiple degenerative muscle diseases On track to initiate first-in-human clinical trial mid-2024 for Duchenne muscular dystrophy Satellos Bioscience Inc...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
- Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024 - Satellos appointed Michael Cross, PhD, MBA, as Chief Business Officer and other key...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle regeneration Satellos is conducting...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life...
TORONTO, June 20, 2022 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change...
TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (TSX-V: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.56 | 0.56 | 0.56 | 0 | 0 | CS |
| 52 | 0.075 | 15.4639175258 | 0.485 | 0.61 | 0.4 | 15013 | 0.49674701 | CS |
| 156 | -0.75 | -57.2519083969 | 1.31 | 1.55 | 0.215 | 40389 | 0.51930449 | CS |
| 260 | -1.94 | -77.6 | 2.5 | 2.5 | 0.215 | 41781 | 0.63393027 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
